drugset / Trial / NCT05547828
Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma
Phase 2
Unknown
20 enrolled
The First Affiliated Hospital of Xinxiang Medical College
BeiGene · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-arm, prospective, open-label clinical study to evaluate the safety and efficacy of tislelizumab combined with chemoradiotherapy in first-line treatment of patients with stage IVb esophageal squamous cell carcinoma.
Timeline
- Start
- 2022-12-20
- Primary completion
- 2024-12-20
- Completion
- 2024-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nab-paclitaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |